ReviewAsian journal of pharmaceutical sciences2022
Biomaterials reinforced MSCs transplantation for spinal cord injury repair.
Review in Asian journal of pharmaceutical sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 35 citations in OpenAlex.
- Smart-responsive electrospun scaffolds (SRES) for neural repair: Recent advances and future prospects.Bioactive materials · 2026Review
- Total flavonoid- and nerve growth factor-loaded gelatin-genipin hydrogel improves repair after spinal cord injury.Neural regeneration research · 2026Article
- Research on GM1 bound bMSCs loaded with SF hydrogel for spinal cord injury repair.Journal of translational medicine · 2026Article
- Exosome-mediated ferroptosis in the tumor microenvironment: from molecular mechanisms to clinical application.Cell death discovery · 2025Review
- Spinal cord injury repair based on drug and cell delivery: From remodeling microenvironment to relay connection formation.Materials today. Bio · 2025Review
- Stem cells in the treatment of myocardial injury-induced cardiomyopathy: mechanisms and efficient utilization strategies.Frontiers in pharmacology · 2025Review
- Revisiting the unobtrusive role of exogenous stem cells beyond neural circuits replacement in spinal cord injury repair.Theranostics · 2025Article
- Emerging technologies in regenerative medicine: The future of wound care and therapy.Journal of molecular medicine (Berlin, Germany) · 2024Review
- Phenolic-enabled nanotechnology: a new strategy for central nervous system disease therapy.Journal of Zhejiang University. Science. B · 2024Review
- An Osteoimmunomodulatory Biopatch Potentiates Stem Cell Therapies for Bone Regeneration by Simultaneously Regulating IL-17/Ferroptosis Signaling Pathways.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- ROS-responsive nanoparticle delivery of ferroptosis inhibitor prodrug to facilitate mesenchymal stem cell-mediated spinal cord injury repair.Bioactive materials · 2024Article
- Tauroursodeoxycholic Acid Inhibited Apoptosis and Oxidative Stress in HMolecular neurobiology · 2024Article
- Transplantation of MiR-28-5p-Modified BMSCs Promotes Functional Recovery After Spinal Cord Injury.Molecular neurobiology · 2024Article
- Initial IL-10 production dominates the therapy of mesenchymal stem cell scaffold in spinal cord injury.Theranostics · 2024Article
- Application of Injectable Hydrogels as Delivery Systems in Spinal Cord Injury.Gels (Basel, Switzerland) · 2023Review
- Bone marrow mesenchymal stem cells and exercise restore motor function following spinal cord injury by activating PI3K/AKT/mTOR pathway.Neural regeneration research · 2023Article
- Novel perspective in transplantation therapy of mesenchymal stem cells: targeting the ferroptosis pathway.Journal of Zhejiang University. Science. B · 2023Review
- Therapeutic Effect of Biomimetic Scaffold Loaded with Human Amniotic Epithelial Cell-Derived Neural-like Cells for Spinal Cord Injury.Bioengineering (Basel, Switzerland) · 2022Article
- Human Umbilical Cord Mesenchymal Stem Cells Encapsulated with Pluronic F-127 Enhance the Regeneration and Angiogenesis of Thin Endometrium in Rat via Local IL-1Stem cells international · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Due to the complex pathophysiological mechanism, spinal cord injury (SCI) has become one of the most intractable central nervous system (CNS) diseases to therapy. Stem cell transplantation, mesenchymal stem cells (MSCs) particularly, appeals to more and more attention along with the encouraging therapeutic results for the functional regeneration of SCI. However, traditional cell transplantation strategies have some limitations, including the unsatisfying survival rate of MSCs and their random diffusion from the injection site to ambient tissues. The application of biomaterials in tissue engineering provides a new horizon. Biomaterials can not only confine MSCs in the injured lesions with higher cell viability, but also promote their therapeutic efficacy. This review summarizes the strategies and advantages of biomaterials reinforced MSCs transplantation to treat SCI in recent years, which are clarified in the light of various therapeutic effects in pathophysiological aspects of SCI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.